Anxiety in primary care

Two structural facts drive this. First, most Americans have a primary care clinician and can reach them faster than they can reach a psychiatrist (see the report on psychiatric wait times). Second, HRSA shortage-area data show that most rural US counties have no practicing psychiatrist, which leaves the primary care clinician as the only option for many patients (see rural and urban access). By design or by necessity, primary care carries the bulk of the load.

The GAD-7 is a seven-item self-report screener developed by Spitzer and colleagues in 2006. A score of 10 or higher is the standard cutoff for likely generalized anxiety disorder, with sensitivity around 89 percent and specificity around 82 percent in the original validation. It also has reasonable performance for panic disorder, social anxiety, and PTSD, though it was designed for GAD. Use in primary care is embedded in many electronic health records and is one of the practical tools primary care clinicians have to catch anxiety that otherwise presents as fatigue, insomnia, or somatic complaints.

In 2023 the US Preventive Services Task Force issued a Grade B recommendation for screening adults age 19-64 for anxiety, based on evidence that screening in primary care can identify unrecognized anxiety and that treatment initiated after screening improves symptoms. The recommendation is for adults not already known to have an anxiety disorder. USPSTF issued an I (insufficient evidence) statement for adults 65 and older, reflecting the thinner evidence base in older adults. See the USPSTF recommendation for the full framework.

Collaborative care embeds a behavioral-health care manager in the primary care team, with weekly caseload review by a consulting psychiatrist. The care manager conducts brief therapy and tracks outcomes with a validated measure. The most-cited anxiety-specific trial is CALM (Roy-Byrne et al., JAMA, 2010), which randomized primary care patients with panic disorder, GAD, social anxiety, or PTSD to collaborative care or usual care and found substantially better anxiety outcomes at 6 and 12 months. Collaborative care for depression has an even larger evidence base and is standard in some health systems; the anxiety-specific rollout has been slower.

Screening finds anxiety; it does not, on its own, treat it. The value of screening depends on what happens after a positive screen: whether the clinician follows up, whether the patient can access treatment, and whether treatment is delivered at adequate intensity. The primary-care share of anxiety prescriptions is a structural feature of the system rather than a claim about optimal care, and any specific figure depends on the data source and the year.

Primary care, not the psychiatrist's office, is where most anxiety care in the United States happens. Primary care clinicians are the most common first point of contact for adults seeking help with anxiety, and they prescribe a large share of the medication used to treat it. This is partly by design and partly by necessity. In much of the country, especially rural areas, there's no psychiatrist within reach, and the primary care clinician is the only option.

Two issues shape anxiety care in this setting. The first is recognition. Anxiety can be missed in a brief primary care visit, especially when a patient presents with physical complaints such as fatigue, sleep problems, or pain. Brief validated screening tools, principally the GAD-7 (Spitzer et al., 2006, with sensitivity around 89 percent and specificity around 82 percent at a cutoff of 10 for GAD), improve detection. The US Preventive Services Task Force has recommended screening adults age 19-64 for anxiety with a Grade B recommendation. The second is depth. A primary care visit is short, which limits the time available for the structured talk-therapy components that the evidence supports.

Models that support primary care, including collaborative care, in which a care manager and a consulting psychiatrist back up the primary care clinician, have evidence for improving outcomes. Roy-Byrne and colleagues' 2010 CALM trial (JAMA) randomized primary care patients with anxiety disorders to collaborative care versus usual care and found meaningfully better anxiety outcomes at 6 and 12 months. Collaborative care is one response to the structural reality that primary care carries most of the load.

The statement that most anxiety care happens in primary care is a well-supported structural fact. Exact figures for the share of prescriptions written by non-psychiatrists depend on the dataset and the year.

GAD-7 is a screening tool, not a diagnostic instrument; a positive screen indicates further evaluation is warranted, not a diagnosis.